LONDON, Aug. 09, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, announces that, on August 8, 2019, Dr. David Ebsworth, Chairman of the Company, purchased a further 60,000 ordinary shares of 5 pence each in the Company (the “Ordinary Shares”) at a price of 50 pence per Ordinary Share and a total purchase price of £30,000. This purchase brings the total purchases made by Dr. Ebsworth during 2019 to approximately £80,000.
Following the acquisition, Dr. Ebsworth will have an interest in the Company of 295,387 Ordinary Shares, representing 0.28% of the Company’s issued share capital.
The notification set out below is provided in accordance with the requirements of the EU Market Abuse Regulation.
| 1 |
Details of the person discharging managerial responsibilities/person closely associated |
| a) |
Name |
David Ebsworth |
| 2 |
Reason for the notification |
| a) |
Position/status |
Chairman |
| b) |
Initial notification/Amendment |
Initial notification |
| 3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
| a) |
Name |
Verona Pharma plc |
| b) |
LEI
|
213800EVI6O6J3TIAL06
|
| 4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
| a) |
Description of the financial instrument, type of instrument |
Ordinary Shares of 5 pence each |
| |
Identification code |
GB00BYW2KH80 |
| b) |
Nature of the transaction |
David Ebsworth purchased 60,000 Ordinary Shares |
| |
|
|
|
| c) |
Price(s) and volume(s) |
Price(s) |
Volume(s) |
| |
|
50 pence per Ordinary Share |
60,000 Ordinary Shares |
| |
|
|
|
| d) |
Aggregated information |
N/A |
|
| |
- Aggregated volume |
|
|
| |
- Price |
|
|
| e) |
Date of the transaction |
8 August 2019 |
| f) |
Place of the transaction |
London Stock Exchange, AIM |
For further information, please contact:
| Verona Pharma plc |
Tel: +44 (0)20 3283 4200 |
Jan-Anders Karlsson, Chief Executive Officer
Victoria Stewart, Director of Communications |
info@veronapharma.com |
| |
|
N+1 Singer
(Nominated Adviser and UK Broker) |
Tel: +44 (0)20 7496 3000 |
| Aubrey Powell / Jen Boorer / Iqra Amin (Corporate Finance) |
|
| Mia Gardner (Corporate Broking) |
|
